The biotech firm targets over half of new prescriptions for its drug MYQORZO by year-end 2026 amid strong Q2 2026 commercial performance.
Cytokinetics aims to capture more than 50% of new-to-brand prescriptions for MYQORZO by the end of 2026. The target follows robust commercial momentum in the U.S. and the drug’s first European launch in Germany during Q2 2026.
Management highlighted solid execution in the quarter, with progress toward expanded global market access. The company also plans to file a supplemental new drug application for non-obstructive hypertrophic cardiomyopathy in Q4.
No immediate market reaction was disclosed in the earnings call summary.